Diabetic kidney disease is the world’s leading cause of kidney failure, silently affecting approximately 1 in 3 people with type 2 diabetes without any early warning symptoms, and a landmark 2026 European Renal Association study of 31,031 patients just revealed that one of the most widely prescribed blood pressure drugs given to these patients may actually be making their diabetic kidney disease 33% worse. If you have type 2 diabetes, understanding this condition — and the rapidly evolving 2026 treatment landscape, may be the most important health decision you make this year.
The study’s finding is alarming precisely because the drug in question, dihydropyridine calcium-channel blockers like amlodipine (Norvasc), is a standard blood pressure treatment that millions of people with diabetes are taking right now, often alongside other kidney-protective medications. Before discussing what to do, here is everything you need to understand about diabetic kidney disease itself.
This article is for informational and awareness purposes. Do not stop or change any medication without speaking to your doctor. If you have concerns about your kidney health, discuss them with your healthcare provider at your next appointment.
The August 2026 ERA Discovery: A Blood Pressure Drug Making Diabetic Kidney Disease Worse
The research was presented at the 63rd European Renal Association Congress in Glasgow, Scotland in August 2026, published in Kidney Medicine journal. It was led by Dr Timna Agur (nephrologist) and Dr Benaya Rozen-Zvi (Director of Nephrology, Rabin Medical Center, Israel), using data from Clalit Health Services, Israel’s largest health maintenance organization.
The design. A retrospective cohort study analyzing 31,031 adults with type 2 diabetes, all of whom were already receiving both RAS inhibitors (ACE inhibitors or ARBs, the standard first-line kidney protection) and SGLT2 inhibitors (the most transformative recent addition to DKD management). Among these patients, 12,172 (39.2%) were also prescribed DCCBs, while 18,859 received other second-line antihypertensives. Participants were followed for a median of approximately 3.5 years.
The drugs in question — the DCCBs. Dihydropyridine calcium-channel blockers are a widely prescribed class of blood pressure drugs including:
- Amlodipine (brand name: Norvasc), one of the most prescribed blood pressure drugs globally
- Nifedipine (Adalat, Procardia)
- Felodipine (Plendil)
These drugs are well-established for blood pressure control in the general population. Their kidney safety in diabetes, specifically when combined with SGLT2 inhibitors, had not been systematically studied at scale before this analysis.
The headline finding. After adjusting for baseline demographic and clinical differences, DCCB use was associated with a 33% higher risk of major adverse kidney events (MAKE) compared with other antihypertensive treatments in the same patient population.
The proposed biological mechanism. DCCBs preferentially dilate the afferent arteriole, the blood vessel entering the kidney’s filtering unit, without an equivalent effect on the efferent arteriole (the exit vessel). This hemodynamic imbalance may increase intraglomerular pressure (the pressure inside the kidney’s filtering units), which over years of use can accelerate glomerular damage and proteinuria, the opposite effect of what RAS inhibitors are trying to achieve. SGLT2 inhibitors also reduce intraglomerular pressure through a different mechanism; adding a DCCB that counteracts this effect may undermine the combination’s kidney-protective benefit.
What the researchers said. “DCCBs are widely used as second-line blood pressure treatments in patients with DKD. Our findings raise important questions about whether DCCBs are always the safest second-line choice,” said Dr Agur.
“These results are of significant clinical importance, given that more than 80% of patients with chronic kidney disease also suffer from hypertension. Selecting the appropriate antihypertensive treatment is critical, as it can directly influence the rate of kidney disease progression,” added Dr Rozen-Zvi.
The essential caveat — before doing anything. This was an observational study. The researchers explicitly cautioned that it cannot establish a direct cause-and-effect link. “People taking DCCBs shouldn’t quit the drugs without first talking to their doctor.” The finding has not yet changed ADA 2026 or KDIGO 2024 guidelines. The appropriate response is a conversation with your nephrologist or endocrinologist, not unilateral medication change.
What Is Diabetic Kidney Disease and Why Does It Have No Symptoms?
Diabetic kidney disease (DKD), also called diabetic nephropathy, is damage to the kidney’s tiny blood-filtering units (glomeruli) caused by chronically elevated blood glucose and high blood pressure working together over years and decades.
How the kidneys fail silently. The kidneys contain approximately 2 million nephrons, individual filtering units each capable of independently filtering blood. The body maintains full kidney function until a substantial proportion of these nephrons are irreversibly damaged, because the remaining nephrons compensate by working harder (hyperfiltration). You can lose 50–60% of kidney function without experiencing a single symptom, because the surviving 40–50% compensates completely.
The first detectable sign: microalbuminuria. Before any symptom appears, a tiny amount of protein (albumin) begins leaking from damaged glomeruli into urine. This microalbuminuria, invisible to the naked eye, detectable only by a urine lab test, is the earliest warning signal available. It means the kidney’s filtering barrier is beginning to fail.
This is why the ADA and KDIGO both require annual urine albumin testing and eGFR blood testing for all people with type 2 diabetes, not when symptoms develop, but every year regardless of how well the person feels.
The global burden. Diabetic kidney disease affects approximately 30–40% of all people with type 2 diabetes, more than 170 million people globally. It is the single leading cause of kidney failure requiring dialysis in most developed countries. In the United States, it accounts for approximately 44% of all new dialysis cases annually.
The type 2 diabetes overview covers the full spectrum of the condition — diabetic kidney disease is its most serious and most preventable long-term complication, and the one most responsive to the kind of systematic, evidence-based management this article describes.
Diabetic Kidney Disease Stages: What Your eGFR and Albumin Numbers Really Mean
Most people with diabetic kidney disease have had their eGFR and albumin results on their lab reports for years, and have never been told what the numbers actually mean in practical terms.
Understanding eGFR (Estimated Glomerular Filtration Rate). eGFR measures how well the kidneys are filtering waste products from the blood, expressed as mL/min/1.73m². It is estimated from a routine blood creatinine measurement.
| eGFR Stage | eGFR Value (mL/min/1.73m²) | Kidney Function | What This Means |
| G1 — Normal | 90+ | Normal | If albuminuria present, DKD is already beginning |
| G2 — Mildly reduced | 60–89 | Mildly reduced | Most people feel completely normal; monitor every 6 months |
| G3a — Mild-moderate | 45–59 | Moderate reduction | Intervention now is critical; nephrology input recommended |
| G3b — Moderate-severe | 30–44 | Significant reduction | Nephrologist referral urgent; prepare for progressive management |
| G4 — Severe | 15–29 | Severe | Prepare for dialysis or transplant planning |
| G5 — Kidney failure | Below 15 | Failure | Dialysis or transplant required |
Understanding Albumin-to-Creatinine Ratio (ACR). ACR measures albumin protein leaking into the urine — the earliest detectable sign of kidney damage.
| ACR Category | ACR Value (mg/g) | What It Signals |
| Normal | Below 30 | No detectable kidney protein leak |
| Microalbuminuria | 30–300 | Early kidney damage, the critical intervention window |
| Macroalbuminuria | Above 300 | Significant kidney damage, aggressive management required |
The combined risk. eGFR stage and ACR category together determine DKD severity and progression risk. A person with eGFR 60 AND macroalbuminuria is at dramatically higher progression risk than someone with eGFR 50 and normal ACR, the albumin leak signals active glomerular damage, not just reduced reserve. Both numbers matter, and both should be tracked annually.
Questions to ask at every diabetes appointment:
- “What is my eGFR and how has it changed over the past year?”
- “What is my urine albumin-to-creatinine ratio?”
- “Should I be seeing a nephrologist at my current levels?”
Managing diabetic kidney disease effectively requires understanding why it develops, how quickly it can progress, and which of the growing number of evidence-based interventions, including some that were not available even two years ago, provide the strongest protection for your kidneys.
The 2026 Treatment Revolution: What’s Now Available to Protect Kidneys in Diabetes
The past three years have transformed the evidence base for diabetic kidney disease management more dramatically than the preceding 20 years combined.
Tier 1 — Standard of Care: Every DKD Patient Should Be on Both
RAS Inhibitors (ACE Inhibitors or ARBs). First-line blood pressure and kidney protection, these drugs dilate the efferent arteriole (the exit vessel from the glomerulus), reducing intraglomerular pressure and proteinuria. ACE inhibitors (lisinopril, ramipril, perindopril) and ARBs (losartan, telmisartan, irbesartan) reduce microalbuminuria, slow eGFR decline, and reduce progression to kidney failure, evidence spans multiple decades of randomized trials. Every person with DKD and measurable albuminuria or hypertension should be on one of these unless contraindicated.
SGLT2 Inhibitors. Originally developed as blood sugar medications, SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga, canagliflozin/Invokana) have become the single most transformative addition to DKD management, now first-line kidney-protective therapy alongside RAS inhibitors per KDIGO 2024 and ADA 2026.
Mechanism in the kidney: SGLT2 inhibitors reduce glomerular hyperfiltration by constricting the afferent arteriole through a tubuloglomerular feedback mechanism, directly reducing intraglomerular pressure. They also reduce tubular metabolic demand, lower blood pressure, reduce proteinuria, and have direct anti-fibrotic effects on kidney tissue. Clinical trial results: approximately 35–40% reduction in kidney failure risk in DKD patients across multiple trials. This is the most powerful kidney-protective medication available for people with type 2 diabetes.
Tier 2 — Important Recent Additions
Finerenone (Kerendia). A new selective mineralocorticoid receptor antagonist approved for DKD. The FIDELIO-DKD and FIGARO-DKD trials found finerenone reduces risk of kidney failure by 18% and major cardiovascular events by 14% in DKD patients already on maximally tolerated RAS inhibitor therapy. ADA 2026 now recommends finerenone for patients with DKD and persistent proteinuria (ACR above 200 mg/g) despite RAS inhibitor plus SGLT2 inhibitor therapy. Note: finerenone can raise potassium, monitoring required.
GLP-1 Receptor Agonists — The FLOW Trial 2026 Update. The FLOW trial found semaglutide (Ozempic) reduced the composite of major kidney events by 24% in people with type 2 diabetes and chronic kidney disease, independent of its blood sugar-lowering effect. The Ozempic side effects and alternative mechanisms article covers GLP-1 drugs comprehensively, the kidney protection data adds a critical dimension. GLP-1 agonists are now considered add-on therapy for high-risk DKD patients whose cardiovascular or kidney risk remains elevated on RAS inhibitors and SGLT2 inhibitors.
Tier 3 — What to DISCUSS With Your Doctor (The 2026 ERA Congress Finding)
The August 2026 ERA Congress analysis raises a critical question about DCCBs, amlodipine, nifedipine, felodipine — as second-line blood pressure agents in DKD patients already on RAS inhibitors and SGLT2 inhibitors. The 33% higher kidney event risk found in 31,031 patients over 3.5 years has not yet changed official guidelines but warrants nephrologist discussion. Alternative second-line options when additional blood pressure control is needed include thiazide diuretics (chlorthalidone, hydrochlorothiazide) and beta-blockers, which do not carry the afferent arteriole hemodynamic concern.
The complete type 2 diabetes medications guide provides the comprehensive treatment landscape within which these kidney-specific decisions sit.
How to Prevent and Slow Diabetic Kidney Disease: The Complete 2026 Evidence-Based Guide
1 — Blood Sugar Control (Most Critical Factor)
Every 1% reduction in HbA1c (e.g., from 8% to 7%) reduces the risk of developing diabetic kidney disease by approximately 30–40% and substantially slows its progression once established. ADA 2026 target HbA1c: below 7% for most adults with type 2 diabetes (individualized with your doctor). The metformin brain pathway research documented metformin’s AMPK-mediated mechanisms, the drug’s metabolic effects that improve blood glucose also directly complement the SGLT2 inhibitors’ kidney-protective mechanisms. Metformin is safe until eGFR falls below 30 mL/min/1.73m².
2 — Blood Pressure Control with the Right Drugs
Hypertension is the second most powerful driver of DKD progression after hyperglycemia. Target: below 130/80 mmHg per ADA 2026 and KDIGO 2024. The choice of blood pressure drug now matters as much as the target, the August 2026 ERA finding makes the second-line agent selection a nephrologist conversation.
Natural blood pressure management complements medication: beetroot juice dietary nitrate provides clinically meaningful additional blood pressure reduction through the nitric oxide pathway. The sugary drinks study documented that childhood high-sugar consumption raises blood pressure trajectory, the same blood pressure that now drives DKD progression.
3 — Protein Intake Moderation
The 2026 Cell Press protein review of 350+ studies found protein restriction lowers blood urea nitrogen and improves kidney disease outcomes in diabetic patients. High protein intake increases glomerular filtration rate, raises intraglomerular pressure, and increases the kidney’s metabolic load. Target for DKD patients: 0.8g/kg/day from predominantly plant-based sources, the level the review identified as optimal for sedentary adults and directly aligned with kidney protection guidelines. This directly contradicts high-protein dietary approaches common in diabetic fitness culture.
4 — Plant-Based Dietary Pattern
The JAMA plant-based diet weight loss study documented simultaneous improvements in insulin sensitivity, liver fat reduction (34.4%), and muscle fat reduction (10.4%), all mechanisms that directly reduce DKD progression. Plant protein sources (legumes, tofu, soy) produce lower metabolic acid load and lower intraglomerular pressure than equivalent animal protein, making them preferable in all DKD stages. The 30% energy density reduction that produces automatic weight loss also directly reduces the visceral adiposity that drives insulin resistance and DKD.
5 — Regular Physical Activity
Exercise improves insulin sensitivity, lowers blood pressure, reduces systemic inflammation, and independently slows eGFR decline through multiple pathways. The Harvard 147,000-person strength training study documented 27% lower neurological death, the cardiovascular protection extends to kidney protection through blood pressure and inflammation reduction. The HKU interval walking study provides the most time-efficient cardiovascular protocol applicable to DKD patients. Even daily stair climbing, the 480,000-person study’s minimum effective dose of six flights, provides blood pressure and cardiovascular conditioning benefits relevant to kidney protection.
6 — Smoking Cessation
Smoking doubles the rate of DKD progression, it directly damages kidney blood vessels, worsens proteinuria independently of blood pressure, and accelerates atherosclerosis that reduces kidney perfusion. Smoking cessation is the single most immediately impactful lifestyle change for DKD patients who smoke.
7 — Weight Management
A 5–10% reduction in body weight in overweight DKD patients meaningfully reduces proteinuria and slows eGFR decline. The vitamin D deficiency and belly fat research identified visceral fat as a systemic inflammatory driver, the same inflammatory environment that accelerates DKD. The belly fat accumulation mechanisms article explains why weight loss in the visceral compartment specifically provides metabolic protection beyond what scale weight suggests.
8 — Avoid Nephrotoxic Medications and Substances
- NSAIDs (ibuprofen, naproxen, diclofenac): reduce kidney blood flow through prostaglandin inhibition, contraindicated for regular use in DKD. Even occasional use should be discussed with your doctor.
- CT contrast dye: discuss kidney risk with your doctor before any contrast-enhanced imaging; temporary metformin cessation and hydration protocols apply.
- “Kidney cleanse” supplements: no evidence of benefit; many contain compounds with nephrotoxic potential. Discuss any supplement with your nephrologist before taking.
- Excessive alcohol: directly nephrotoxic and raises blood pressure; limit to occasional moderate use or abstain.
The Lp(a) hidden heart risk research is directly relevant to DKD management, elevated Lp(a) and DKD compound cardiovascular risk synergistically in type 2 diabetes, making Lp(a) testing a worthwhile addition to the annual diabetes review for people with progressive DKD.
Diabetic Kidney Disease Diet — Practical Guidance by Stage
Stages G1–G2 (Early DKD):
- Sodium below 2,300mg/day, reduces blood pressure and proteinuria
- Protein: 0.8g/kg/day from predominantly plant sources (legumes, tofu, soy, quinoa)
- Anti-inflammatory focus: olive oil, fatty fish 2–3 times weekly, leafy greens, berries
- Eliminate ultra-processed foods, red meat, processed meat
- Limit phosphate additive-containing products (soft drinks, processed meats, look for “phosphate” on labels)
Stage G3 (Moderate DKD):
- Sodium below 2,000mg/day
- Begin monitoring potassium if on ACE inhibitors/ARBs (these raise blood potassium), a doctor or renal dietitian should guide limits if potassium runs high
- Continue phosphorus monitoring, limit processed foods with phosphate additives
- Protein: 0.6–0.8g/kg/day with renal dietitian guidance
- Consistent carbohydrate distribution across meals for blood sugar control
Stages G4–G5 (Severe DKD):
- Potassium restriction individualized based on blood levels, not all G4 patients need restriction
- Phosphorus restriction: limit dairy, beans, nuts, and avoid phosphate-additive foods
- Protein: may drop to 0.6g/kg/day under nephrologist supervision
- Fluid restriction if required as eGFR falls below 15–20
- A registered renal dietitian is essential at this stage, DKD dietary management at G4+ is complex and requires individualization
The gut health and microbiome research is directly relevant to DKD diet: uremic toxins (indoxyl sulfate, p-cresol) produced by gut bacteria contribute to kidney damage progression. Prebiotic fiber from plant foods shifts gut bacteria away from uremic toxin-producing species, providing gut-mediated kidney protection alongside the direct dietary protein and phosphorus benefits. The gut-brain memory axis study’s documentation of junk food’s permanent damage to gut-brain signaling pathways is equally relevant to the gut-kidney axis, the same dietary patterns drive both forms of organ damage.
Diabetic Kidney Disease Warning Signs That Appear Late
The following symptoms appear only when substantial kidney function is already lost. Their absence is not reassurance, it is the nature of the disease.
Physical symptoms (appear after >50% kidney function loss):
- Swelling (oedema) in feet, ankles, legs, or around the eyes, from protein loss and fluid retention
- Foamy or bubbly urine, protein leaking at levels visible in toilet water
- Fatigue and weakness disproportionate to activity, anaemia from the kidney’s reduced erythropoietin production
- Shortness of breath, fluid accumulating around the lungs
Advanced symptoms (appear near dialysis threshold):
- Persistent nausea, vomiting, and loss of appetite, uremia (toxin accumulation)
- Generalized skin itching, uremic compounds depositing in skin
- Difficulty concentrating or confusion, uremic encephalopathy
- Reduced or absent urine output, very late stage
The one action point. By the time any of these symptoms appear, you have likely already lost more than half your kidney function, and the window for intervention that could have preserved that function has passed. Annual urine albumin and eGFR testing, ordered proactively by your diabetes care team when you have no symptoms, is the only meaningful early warning system available.
Who Needs to See a Nephrologist — And When
Your GP or endocrinologist should refer you to a nephrologist when any of these apply:
- eGFR falls below 45 mL/min/1.73m² (Stage G3b or below)
- eGFR is declining rapidly: more than 5 mL/min/1.73m² per year
- Macroalbuminuria (ACR above 300 mg/g) not responding to standard treatment
- Unexplained deterioration in kidney function
- Complex medication management requirements (potassium management, finerenone initiation, dialysis preparation)
- Planning a pregnancy with existing DKD
Questions to bring to your nephrologist:
- “Should I be on an SGLT2 inhibitor for kidney protection, and if so, which one?”
- “Should I be on finerenone (Kerendia) given my current albuminuria level and therapy?”
- “I’ve read about the 2026 ERA Congress finding that DCCBs may raise kidney risk by 33% in diabetes patients on SGLT2 inhibitors and RAS inhibitors, is my blood pressure regimen optimal for my kidney situation?”
- “What is my estimated eGFR trajectory if current trends continue?”
- “At what eGFR should we begin discussing dialysis access preparation?”
What to do RIGHT NOW if you have type 2 diabetes and have NOT had a kidney function test in the past year: Book a routine diabetes review. Ask your doctor: “I’d like my eGFR and urine albumin-to-creatinine ratio checked today.” These are simple blood and urine tests that can be done at any routine appointment. If you are in the UK: these tests should be included in your annual NHS diabetes review automatically. If they are not being offered, request them explicitly.
The biological aging research connects diabetic kidney disease to accelerated epigenetic aging, each of the lifestyle interventions covered in this article (exercise, plant-based diet, blood sugar and blood pressure control) simultaneously slows the biological aging clock measured by DunedinPACE while slowing DKD progression. These are not separate interventions, they are the same biological protection, measured by different tools.
The DCCB Blood Pressure Drug Alarm: A Message for Diabetes Patients on Amlodipine
Millions of people with type 2 diabetes and high blood pressure are currently taking amlodipine (Norvasc), nifedipine, or felodipine alongside their standard diabetes kidney medications — often without anyone having told them this combination might be reconsidered following the August 2026 ERA Congress finding.
Concrete action steps:
Step 1: Check your current medication list. Is any of the following in your current blood pressure prescriptions: amlodipine, nifedipine, felodipine, Norvasc, Adalat, or Plendil?
Step 2: Bring this statement to your next appointment. “I read about the 2026 ERA Congress study, published in Kidney Medicine journal, finding that DCCBs are associated with 33% higher major kidney event risk in type 2 diabetes patients already on SGLT2 inhibitors and RAS inhibitors. Could we review whether my blood pressure regimen is optimal for my kidney health, and whether alternatives like thiazide diuretics or beta-blockers might be preferable?”
Step 3: Do NOT stop any blood pressure medication independently. Uncontrolled hypertension causes immediate, measurable kidney damage that far outweighs any theoretical medication risk. Blood pressure control itself is kidney-protective, the question is which drug achieves that control most safely in DKD. Only your nephrologist or cardiologist can make that individualized determination.
The wider context for the medication finding. The Lp(a) article established that cardiovascular drug selection matters, not just reaching targets but using the right tools. The DCCB finding extends this principle to kidney protection: in DKD specifically, the mechanism by which blood pressure is lowered affects kidney outcomes, not just the number achieved.
FAQs About Diabetic Kidney Disease
What are the earliest warning signs of diabetic kidney disease? There are no symptoms in early stages. The first detectable sign is microalbuminuria, protein leaking into urine, detectable only by laboratory testing. This is why annual urine albumin and eGFR testing for all people with type 2 diabetes is non-negotiable. Waiting for symptoms means waiting until more than half of kidney function is already lost.
How quickly does diabetic kidney disease progress? Without optimal treatment: 5–15 mL/min/1.73m² eGFR decline per year, reaching failure in 10–20 years. With modern optimal treatment (SGLT2 inhibitors, RAS inhibitors, blood pressure below 130/80, HbA1c below 7%): 1–2 mL/min/1.73m² per year, a near-normal aging rate. Early intervention is the most powerful modifier.
Can diabetic kidney disease be reversed? Full reversal is not achievable, lost nephrons do not regenerate. However, progression can be dramatically slowed or stabilized. In early stages with aggressive treatment, some patients show albuminuria reduction and eGFR stabilization. The realistic goal is stopping the clock, not turning it back.
What eGFR level means my kidneys are failing? eGFR below 15 indicates kidney failure (Stage G5). Stage G4 (15–29) requires urgent preparation. Stage G3b (30–44) warrants urgent nephrology referral. eGFR below 45 in any person with diabetes should trigger nephrologist referral regardless of symptoms.
Which blood pressure drugs are safest for diabetic kidney disease? First-line: ACE inhibitors or ARBs (RAS inhibitors). When additional treatment is needed: the August 2026 ERA Congress analysis of 31,031 patients found DCCBs (amlodipine, nifedipine, felodipine) associated with 33% higher kidney event risk in DKD patients on SGLT2 inhibitors and RAS inhibitors. Discuss alternative options with your nephrologist, but do not stop any medication without medical guidance.
Does metformin cause kidney damage? No, metformin does not damage kidneys. However, it accumulates when eGFR falls below 30 mL/min/1.73m² and can cause lactic acidosis. Safe to use until eGFR falls below 30; reduce dose between 30–45; avoid below 30. Safe at all earlier DKD stages.
Can Ozempic/semaglutide protect the kidneys? Yes, the FLOW trial found semaglutide reduced major kidney events by 24% in DKD patients, independent of blood sugar effects. GLP-1 agonists are now add-on therapy for high-risk DKD patients.
What is the best diet for diabetic kidney disease? Early DKD: 0.8g protein/kg/day from plant sources, sodium below 2,300mg/day, anti-inflammatory foods. Advanced DKD: renal dietitian guidance on potassium, phosphorus, and protein. Plant protein throughout all stages is preferred over animal protein for its lower acid load and intraglomerular pressure effect.
At what point does diabetic kidney disease require dialysis? Typically when eGFR falls below 10–15 with uremic symptoms. Dialysis access preparation should begin around eGFR 20–25. Modern optimal treatment can delay dialysis need by 10–20 years from early-stage intervention.
How is diabetic kidney disease different from other kidney diseases? DKD is caused by chronic hyperglycemia damaging glomerular units, characterized by Kimmelstiel-Wilson nodules, thickened glomerular basement membranes, and podocyte loss. It almost always co-occurs with diabetic retinopathy and neuropathy. Its management is specifically informed by SGLT2 inhibitors, GLP-1 agonists, and finerenone, treatments with dedicated DKD-specific evidence.
This article is for informational and awareness purposes only. Do not stop or change any medication without speaking to your healthcare provider. Diabetic kidney disease requires specialist medical management.
